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Abstract
Vascular endothelial growth factor (VEGF) is a mitogen that plays a crucial role in angio-
genesis and lymphangiogenesis. It is involved in tumor survival through inducing tumor 
angiogenesis and by increasing chemoresistance through autocrine signaling. Because 
of its importance in tumor formation and survival, several medications have been devel-
oped to inhibit VEGF and reduce blood vessel formation in cancer. Although these medi-
cations have proven to be effective for late-stage and metastatic cancers, they have been 
shown to cause side effects such as hypertension, artery clots, complications in wound 
healing, and, more rarely, gastrointestinal perforation and fistulas. Current research in 
using anti-VEGF medication as a part of cancer treatments is focusing on elucidating the 
mechanisms of tumor resistance to VEGF medication, developing predictive biomarkers 
that assess whether a patient will respond to VEGF therapy and creating novel treatments 
and techniques that increase the efficacy of antiangiogenic medication. This chapter aims 
to review the role of VEGF in tumor angiogenesis and metastasis, the structure and func-
tion of VEGF and its receptors, and VEGF’s role in cancer are discussed. Furthermore, 
tumor therapies targeting VEGF along with their side effects are presented and, finally, 
new directions in anti-VEGF therapy are considered along with the challenges.
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1. Introduction
Oxygen and nutrients are critical to the functioning and survival of cells in the body. This 
need is met through the creation of an extensive vascular system, which is maintained 
through the process of angiogenesis, and the creation of blood vessels from the existing vas-
culature [1]. In the angiogenesis process, endothelial cells initially respond to changes in the 
local environment and migrate toward the growing tumor. The endothelial cells then migrate 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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together forming tubular structures that are ultimately encapsulated by recruiting periendo-
thelial support cells to establish a vascular network that facilitates tumor growth and metas-
tasis. Angiogenesis is subject to a complex regulatory system of both pro- and antiangiogenic 
factors after a tissue is fashioned [1–3] and deregulating angiogenesis–a classic trademark 
of cancer–leads to an aberrant microenvironment and promotion of tumor progression. 
Angiogenesis is initiated by the binding actions of vascular endothelial growth factor (VEGF) 
and fibroblast growth factors (FGF1/2) [4].
VEGF is an essential proangiogenic factor whose production is itself extensively regulated 
by a plethora of growth factors, cytokines, and other extracellular molecules produced in 
response to the various metabolic and mechanical conditions present in the cell’s environ-
ment [2–6]. VEGF plays a pivotal role in tumor angiogenesis. The overexpression of VEGF 
is one of the central factors that leads to the onset and progression of cancer. In order 
to sustain their growth beyond any current size, tumors require an increased supply of 
blood, and this is achieved through the expression and secretion of VEGF, which stimu-
lates the induction of new blood vessels around the tumor. Furthermore, the cancer cells, 
through the action of this subfamily of growth factors, invade other organs and areas of the 
body (metastasis) [4]. Consequently, VEGF and the resulting tumor angiogenesis present 
an attractive therapeutic target in the treatment of cancer. Inhibitors of VEGF/angiogenesis 
have been garnering interest and studied for their therapeutic application in most solid 
tumors [7, 8]. Moreover, a series of preclinical studies have revealed that anti-VEGF com-
pounds increase the efficacy of ensuing antitumor treatment, although the mechanism of 
this effect is unclear [9].
2. Structure and function of VEGF and VEGFRs
VEGF is a dimeric glycoprotein secreted by cells that is able to induce permeability of blood 
vessels and promotes angiogenesis. The VEGF family contains seven members, all part of 
the platelet-derived growth factor (PDGF) supergene family: VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, VEGF-F, and PlGF [10, 11]. All members contain a core region comprised 
of eight cysteine residues forming a cysteine knot motif. These residues are involved in both 
inter- and intramolecular disulfide bonds at one end of a central four-stranded β-sheet within 
each monomer, which dimerizes in antiparallel fashion [11]. VEGFs A–D and PlGF are all 
produced in humans, whereas VEGF-E is produced in the Orf virus, has a 25% amino acid 
homology to mammalian VEGF, and lacks a heparin-binding domain [12]. VEGF-F is pro-
duced in snake venom and varies its structure and function by species, helping to produce a 
variety of venom [13].
The VEGF-A gene contains eight different exons that create six different isoforms through 
alternative splicing. These isoforms have lengths (in amino acids) of 121, 145, 165, 183, 189, 
and 206 that are produced by the alternate splicing of a single gene containing eight exons, 
and they all contain exons 1–5 and 8. All forms of VEGF-A except for VEGF-A121 can bind to 
heparin [11]. VEGF165 is the one most commonly secreted by tumor cells and acts most strongly 
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on endothelial cells to lead them to form new capillaries. VEGF-B exists as two isoforms of 
lengths 167 and 186 amino acids and has been shown to act as a cell survival factor while 
exhibiting little proangiogenic effect [14]. VEGF-C and VEGF-D are resealed proteolytically 
from their respective precursor proteins and play important roles in regulating lymphangio-
genesis [10, 11]. PlGF upregulates angiogenesis through binding to VEGFR-1 (thereby freeing 
VEGF-A to bind to VEGFR-2) and exists in four isoforms of amino acid lengths 131, 152, 203, 
and 224 [15]. It has also been shown to induce a specific phosphorylation and activation of 
c-Jun N-terminal kinase (JNK) and p38 [16].
VEGF signaling pathway plays a major role in angiogenesis. VEGF receptors (VEGFRs) are 
type V receptor tyrosine kinases (RTKs) activated upon ligand-mediated dimerization [17]. 
Two high-affinity VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR), have been 
identified in endothelial cells. Flk-1 (R2) has been shown to play a major role in tumor angio-
genesis. In all, there are three types of receptors, with VEGFR-3 only binding to VEGFs –C 
and –D. Each of the three types of receptor (VEGFR-1, -2, and -3) is composed of seven immu-
noglobulin-like domains in the extracellular region, a transmembrane region, and a tyrosine 
kinase sequence with a kinase insert domain [11].
Signaling of VEGF is initiated via binding to its receptors, which are tyrosine kinases that are 
able to transphosphorylate tyrosine residues of SH2 domain-containing signaling molecules, 
thus activating kinase-dependent transcription factors known as STAT proteins, to modulate 
cell responses induced by VEGF. VEGFR-1 and -2 are both involved in endothelial cell func-
tion and angiogenesis [18], while VEGFR-3, to which only VEGFs –C and –D can bind, plays a 
critical role in lymphangiogenesis and primarily involved in normal embryonic development 
[11]. VEGF-1 has also been shown to be required in inducing the migration of monocytes and 
macrophages [19]. Neuropilins-1 and -2 are important coreceptors for VEGF signaling and 
increase the affinity of VEGF-A165 for its receptors [5]. Refer to Figure 1 for a summary of how 
each VEGF pairs with each VEGF receptor.
VEGF is heavily involved in promoting angiogenesis and research suggests that it also plays 
a role in regulating intussusceptive angiogenesis as well. In sprouting angiogenesis, hypoxia 
induces parenchymal cells to release VEGF-A into the extracellular matrix (ECM). VEGF-A 
then causes tip cells to produce the Delta-like-4 (Dll4) ligand, which is a membrane-bound 
ligand that serves to activate the Notch receptor, a highly conserved transmembrane recep-
tor that regulates cell proliferation, cell fate, and cell death in metazoans on neighboring 
cells through cell to cell contact [20]. Dll4 then inhibits migratory behavior through activat-
ing the Notch receptor on neighboring stalk cells. Tip cell filopodia, actin-rich protrusions 
on the cell membrane that serve as a mechanism for a cell to explore its environment, sense 
a gradient in VEGF-A and align their sprouting to this gradient. The tip cell then anchors 
itself onto the substratum while actin microfilaments in the filopodia contract, pulling the 
tip cell toward the VEGF-A source while stalk cells proliferate. When the tip cells from dif-
ferent sprouts meet, they fuse to become a functional capillary through which blood can 
flow [1]. The function of VEGF in sprouting angiogenesis is less well understood, although it 
is suspected that VEGF cooperating with angiopoietin-1 (Ang-1) plays a role in stimulating 
the process [21, 22].
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3. The role of VEGF in cancer
Tumors need oxygen to survive. At first, they are able to obtain enough oxygen by coopting 
the surrounding vasculature, altering its morphology, physiology, and response to therapy in 
the process. However, when a tumor becomes too large to be sufficiently supplied by existing 
vasculature, an “angiogenic switch” is turned on, and the tumor begins the process of tumor 
angiogenesis, thereby creating its own vasculature for an oxygen supply [23–26].
The angiogenic switch is triggered by hypoxia occurring when the tumor becomes too large 
for oxygen to diffuse from existing vasculature to tumor cells [27]. Hypoxia induces the pro-
duction of VEGF in tumor cells through hypoxia-inducible factor-1α (HIF-1α) [25, 27], a mas-
ter transcriptional factor that regulates a group of downstream genes including VEGF that 
promote angiogenesis and metastasis, while inhibitors of angiogenesis such as angiostatin 
and interferon are downregulated [23]. A suite of other proangiogenic genes (such as Ang-1 
and -2) and regulatory mechanisms (such as micro-RNAs) are also regulated by the hypoxia-
induced HIF pathway [25]. Tumor cells then release VEGF into the surrounding extracellular 
space, which binds to VEGF R of surrounding or nearby endothelial cells, promoting local 
angiogenesis and forming tumor-associated microvessels in order to delivering oxygen-car-
rying blood to the tumor.
Compared with normal vasculature, tumor vessels are highly irregular and inefficient at 
delivering nutrients. They branch irregularly, follow a tortuous path, are far larger than their 
normal counterparts, are unusually permeable to large molecules, have a high interstitial 
Figure 1. A summary of the functions of each form of VEGF and PlGF and each VEGF receptor. VEGFR-1 regulates cell 
migration and gene expression in monocytes and macrophages; VEGFR-2 regulates vascular endothelial functions; and 
VEGFR-3 regulates lymphatic endothelial functions. VEGF-A is a proangiogenic factor; VEGF-B is a prosurvival factor; 
VEGF-C and –D regulate lymphangiogenesis; VEGF-E is found in the Orf virus; and PlGF encourages VEGF-A to bind 
to VEGFR-2, thereby stimulating angiogenesis, and encourages the transcription of JNK and p38.
Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy388
pressure, and are inefficient at carrying blood [26, 28]; these abnormalities of the tumor vas-
culature result in poor delivery of nutrients, causing certain areas of the tumor to be chroni-
cally hypoxic, stabilizing the HIF/VEGF signaling pathway described above and therefore 
resulting in even more tumor vasculature [25]. The overproduction of VEGF-A results in an 
abundance of tip cells from the Dll4 signaling pathway, which in part causes the malformed 
vasculature associated with tumors through excessive branching of these tip cells [25, 29].
Tumor blood vessel can be divided into six general classes: (1) mother vessels, which are 
enlarged, tortuous, thin-walled, lacking in pericytes, and highly permeable; (2) capillaries, 
which are similar to normal capillaries; (3) glomeruloid microvascular proliferations, which 
are tangles of vessels situated within a mixture of disordered pericytes; (4) vascular malforma-
tions, which are large vessels with an irregular coat of smooth muscle cells; (5) feeder arteries; 
and (6) draining vessels, which are enlarged, serpentine smooth muscle cell-coated vessels that 
supply and drain the blood vessels within the tumor [30]. The irregular pericyte and smooth 
muscle cell formations on these vessels, which in normal vasculature serve to enhance tight 
junctions and decrease leakiness, serve to decrease vessel efficacy in tumor angiogenesis [31].
Oncogenes play a prominent role in triggering the angiogenic switch. Expression of the H-Ras 
oncogene in the immortalized rat intestinal epithelial cell line IEC-18 led to the upregulation 
of VEGF and a significant increase of in vivo vascularization [32]. Ras signaling also results in 
the stabilization of the resulting mRNAs and possible enhancement of their transcription [33]. 
The p53 suppressor gene normally serves to downregulate VEGF while upregulating throm-
bospondin-1, an antiangiogenic factor; mutations in these genes serve to increase the activity 
of VEGF [34, 35]. p53 acts as a foil to C-Myc, a gene that triggers the expression of VEGF while 
downregulating thrombospondin-1. In tumors, mutations in p53 serve to increase the activity 
of c-Myc, thereby increasing the activity of VEGF [34].
Compared to VEGF-A, VEGF-B plays an insignificant role in angiogenesis. Rather, it acts 
as a potent survival factor, inhibiting the production of several proapoptotic factors such as 
BH-3-related proteins. The prosurvival effects of VEGF-B are mediated by both VEGFR-1 and 
the coreceptor NP-1 [36, 37]. More recent research suggests that VEGF-B may trigger tumor 
angiogenesis through a VEGF-A-independent pathway and that it may even be a prognostic 
marker for cancer metastasis [38].
VEGF-C and VEGF-D are both heavily involved in lymphangiogenesis. In tumors, these 
two forms of VEGF are overexpressed and activate VEGFR-3 by means of a paracrine sig-
naling loop, thereby encouraging lymphatic growth within the tumor [39, 40]. Lymphatic 
vessels created through tumor angiogenesis tend to be larger than normal, enhancing 
the delivery of tumor cells to the lymph nodes, from which metastasis can occur (while 
VEGFR-3 activation causes lymphatic vessels to sprout, it should be noted that VEGFR-2 
causes the vessels to become dilated) [41]. For example, metastasis of breast cancer occurs 
primarily through the lymphatic system, and VEGF-C has been shown to enhance tumor 
metastasis in this disease [42]. Because both lymphatic vessels and blood vessels provide 
nutrients and a metastatic pathway for a tumor, vascular density (lymphatic vessels den-
sity or blood vessel density) within the tumor may be a prognostic factor of metastatic 
potential [41, 43].
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4. Anti-VEGF medications
Because of tumor dependence on VEGF for growth and survival, much work has been put 
into developing VEGF inhibitors for use in the clinic. Most of these inhibitors fall under two 
broad categories that differ in structure and mechanism of action: small-molecule inhibitors 
(SMIs) and monoclonal antibodies (mAbs). Table 1 contains a list of the anti-VEGF medica-
tions mentioned in this chapter, their types, FDA approval dates, the forms of cancer they are 
approved to treat, and some common side effects associated with their use.
Some SMIs targeting VEGF signaling pathway are able to pass through the cellular membrane 
and interact with the cytoplasmic domain of receptor tyrosine kinases (RTKs) [44, 45]. Most 
act as competitive inhibitors with ATP. As the ATP binding site is common to all RTKs, speci-
ficity in the SMI is created by engineering the part of the molecule not similar to ATP [44]. 
Small molecule tyrosine kinase inhibitors (SMTKIs) can be divided into three broad catego-
ries: those that hydrogen bond with the ATP binding site of the enzyme’s active conformation 
(type I), those that hydrogen bond with the hydrophobic pocket directly next to the ATP bind-
ing site in the enzyme’s inactive conformation (type II), and those that bond covalently and 
irreversibly with specific cysteine residues on the kinase (type III) [44].
Sunitinib is a type I SMTKI [44] that is able to inhibit RTKs containing a split-kinase domain, 
such as VEGFRs -1, -2, and -3; PDGFRs –A and –B; cKIT; FLT3; CSF-1R; and RET [46]. The 
inhibition of the RTKs blocks signal transduction, thereby preventing tumor growth and 
angiogenesis among other processes. Sunitinib is administered orally in a recommended dose 
of 50 mg once daily for 4 weeks followed by a 2-week rest [47]. The medicine is currently 
FDA approved for use in progressive well-differentiated pancreatic neuroendocrine tumors 
in patients with unresectable, locally advanced, or metastatic disease; metastatic renal cell 
carcinoma; and gastrointestinal stromal tumors after intolerance to imatinib mesylate [46].
Sorafenib is a type II SMTKI [45]. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, and Kit; 
therefore, it operates through a dual mechanism of action, inhibiting both tumor growth and 
angiogenesis [48]. Sorafenib is administered in a recommended dose of 400 mg twice daily 
around mealtimes [47]. The medicine is FDA approved for use in recurrent or metastatic pro-
gressive differentiated thyroid carcinoma, advanced renal cell carcinoma, and unresectable 
hepatocellular carcinoma [49].
Vandetanib is a type III SMTKI [44]. It inhibits VEGFR-2, EGFR, and RET, blocking several 
signal transduction pathways that control tumor growth and angiogenesis [50]. Vandetanib 
was approved in 2011 for use against unresectable, locally advanced, or metastatic med-
ullary thyroid cancer. The recommended daily dose of the medicine is 300 mg per day, 
administered orally [51].
In contrast to small molecule inhibitors, monoclonal antibodies (mAbs) cannot translocate 
through the plasma membrane to interact with the cytoplasmic domains of RTKs; they are, 
however, more specific in action than SMIs [45]. mAbs used in antiangiogenic therapies can 
be divided into two broad categories: those that bind to VEGF and inhibit VEGF’s ability to 
bind with its receptors, and those that bind to VEGFRs and inhibit ligand-receptor interaction 
and activate immune responses.
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Medicine Type of 
medication
FDA approval 
date
Types of cancers  
approved for to date
Common Grade 3-4 
side effects
Apatinib [114] SMI N/A N/A N/A
Bevacizumab [125] mAb 26-Feb-04 Metastatic colorectal cancer, 
nonsmall cell lung cancer, 
glioblastoma, metastatic renal 
cell carcinoma, cervical cancer (in 
combination with chemotherapy), 
platinum-resistant recurrent 
epithelial ovarian, fallopian tube, 
or primary peritoneal cancer in 
combination with chemotherapy 
FDA approval for the use of 
bevacizumab in metastatic HER2-
negative breast cancer was revoked 
on 18 Nov. 2011 on account 
of potentially life-threatening 
side effects and the few benefits 
associated with its use
Sensory neuropathy, 
hypertension, fatigue, 
neutropenia, vomiting, 
diarrhea
Cabozantinib [116] SMI 25-Apr-16 Renal cell carcinoma in patients  
who have received prior 
antiangiogenic therapy
Abdominal pain, 
pleural effusion, 
diarrhea, and nausea
Pazopanib [126] SMI Oct-09 Advanced renal cell carcinoma, 
advanced soft tissue sarcoma
Diarrhea, 
hypertension, and 
proteinuria 
Ramucirumab [96] mAb 21-Apr-14 Gastric/gastroesophageal junction 
adenocarcinoma (with and without 
paclitaxel), with docetaxel for 
platinum-resistant metastatic 
nonsmall cell lung cancer, with 
FOLFIRI for metastatic colorectal 
cancer
Hypertension, 
hyponatremia, 
neutropenia, 
pneumonia
Sorafenib [50] SMI 20-Dec-05 Advanced renal cell carcinoma, 
unresectable hepatocellular 
carcinoma, progressive  
differentiated thyroid carcinoma
Diarrhea, hand-foot 
syndrome
Sunitinib [46] SMI 26-Jan-06 Gastrointestinal stromal tumor, 
advanced kidney cancer,  
pancreatic neuroendocrine tumors
Hypertension, 
diarrhea, nausea, 
vomiting
Vandetanib [52] SMI 6-Apr-11 Medullary thyroid cancer in  
patients with unresectable, locally 
advanced, or metastatic disease
Diarrhea/colitis, 
hypertension and 
hypertensive crisis, QT 
prolongation, fatigue, 
and rash
Zif-Aflibercept  
[127]
VEGF-Trap 
(hybrid of 
VEGFR-1 binding 
domain and 
VEGFR-2 domain 
3)
3-Aug-12 Metastatic colorectal cancer that  
is resistant to an oxaliplatin- 
containing regimen
Neutropenia, diarrhea, 
hypertension, 
leukopenia, stomatitis, 
fatigue, proteinuria, 
and asthenia
33C3 [57] mAb N/A N/A N/A
Table 1. FDA approvals for antiangiogenic drugs.
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Perhaps the most well-known mAb targeting VEGF is bevacizumab, first approved in the EU 
in January 2005 [52]. The medicine targets all forms of VEGF-A, thereby inhibiting its ability 
to activate angiogenesis [53]. 2C3 is another mAb that binds to VEGF, preventing it from inter-
acting with VEGFR-2, but not VEGFR-1; it blocks the growth of blood vessels in tumors and 
inhibits increases in vascular permeability [54]. IMC1121B (ramucirumab) binds to the ligand 
binding site of VEGFR-2 [55]. 33C3 is an antibody that binds to Ig domains 4-7 of VEGFR-2 
and therefore, on account of binding to VEGFR-2 as opposed to a VEGF molecule, has the 
potential to act independently of VEGF concentration [56].
A type of VEGF inhibitor that defies simple classification into one of these two categories 
was developed recently as VGEF-trap, otherwise known as aflibercept. Aflibercept is a fusion 
protein consisting of the VEGFR-1 and VEGFR-2 binding domains and the Fc region of the 
IgG1 antibody [57, 58]. The protein binds to VEGF-A, VEGF-B, and PlGF, inhibiting activa-
tion of VEGFR-1 and VEGFR-2 and thereby inhibiting angiogenesis [57, 58]. Aflibercept was 
approved as Zaltrap on 3 August 2012 for use in combination with a FOLFIRI (folinic acid, 
fluorouracil, and irinotecan) chemotherapy regimen in adults with colorectal cancer [59], and 
has been shown to provide significant benefits in OS and PFS [60].
5. Side effects of anti-VEGF medications
No metabolically active tissue in the human body is more than a few hundred micrometers 
away from a capillary vesicle. The extensive nature of the vascular system in humans is pro-
duced and maintained through angiogenesis; changes in metabolic activity lead to changes in 
demand for oxygen which in turn regulate angiogenesis [1]. Therefore, angiogenesis inhibitors 
are bound to have adverse side effects. These side effects are generally less severe than those 
encountered from chemotherapy, although they can still be life-threatening [61]. Common 
side effects include hypertension, arterial thromboembolic events (ATEs), cardiotoxicity, and 
problems with bleeding, gastrointestinal perforation, and wound healing. See Table 2 for a 
description of grades of adverse events.
Perhaps the most well documented side effect of angiogenesis inhibitors is hypertension. 
VEGF has been shown to decrease blood pressure; for example, in a phase I clinical trial 
(the VIVA trial, a double-blind placebo-controlled study), recombinant VEGF was shown to 
decrease systolic blood pressure by as much as 22% [62]. This decrease in blood pressure is 
caused by the generation of blood capillaries, which increases the total cross-sectional sur-
face area available for blood to flow and thereby reduces blood pressure, and VEGF-induced 
vasodilation, which occurs when VEGF induces the production of nitric oxide and PGI2 as 
part of its signal transduction pathway [63]. VEGF inhibitors therefore cause hypertension by 
inhibiting the production of nitric oxide and PGI2, leading to vasoconstriction and an increase 
in blood pressure [64, 65]. Hypertension caused from VEGF inhibition can be managed using 
standard therapies, such as angiotensin-converting enzyme inhibitors, beta blockers, calcium 
channel blockers, diuretics, and angiotensin II receptor blockers [66].
VEGF-dependent interactions between the glomeruli and endothelial cells are also inhibited 
through anti-VEGF therapies (such as bevacizumab, sunitinib, and sorafenib [67]), leading 
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to proteinuria, a common side effect in anti-VEGF treatment [65, 68]. Inhibition of the VEGF 
signaling pathway leads to the suppression of nephrin, which in turn leads to a decrease in 
maintenance of the glomerular slit diaphragm [68]. Luckily, most instances of proteinuria are 
mild, presenting as only grades I and II, although more severe proteinuria has been reported 
in a share of cases [67, 68].
Treatment with VGEF inhibitors is also associated with an increased risk of arterial thrombo-
embolic events (ATEs) [65, 69, 70]. This increased risk is caused by a reduction in the regen-
erative capacity of endothelial cells and can diminish antiapoptotic factors while encouraging 
procoagulant changes in the blood vessels [70]. The rate of venous thromboembolic events 
does not seem to be affected by VEGF inhibition, at least when comparing bevacizumab 
with chemotherapy and chemotherapy alone [69]. It is recommended that patients on anti-
VEGF therapy who develop an ATE be taken off the therapy immediately [65]. The use of 
aspirin during therapy has been shown to increase the likelihood of grade 3 and 4 bleeding 
events, although no significant difference has been found between aspirin users in control 
and bevacizumab-treated groups [69]. Patients with a history of ATEs and older patients are 
at greater risk in developing a thromboembolic event when using VEGF inhibitors such as 
bevacizumab [69].
Cardiotoxicity is also a common side effect of VEGF inhibition, and has been observed in 
patients on bevacizumab, sunitinib, and sorafenib. The exact mechanisms of this toxicity are 
often unclear, and they may either have to do with inhibition of VEGF, inhibition of other 
signaling pathways concomitantly with VEGF, or both. Cardiomyopathy has been observed 
in sunitinib monotherapy in a phase I/II trial in which 11% of all participants (8/75) had a car-
diovascular event [71]. Another study found evidence that sunitinib induces cardiotoxocity 
through the inhibition of the AMPK signal transduction pathway [72]. Moreover, bevacizumab 
given after acute myelogenous leukemia chemotherapy resulted in an increase in cardiovas-
cular toxicity, although the mechanisms for this toxicity remain unknown [73]. Sorafenib has 
also been demonstrated to cause cardiotoxicity in mice due to myocyte necrosis [74].
Grade Description Example with gastric fistula
I Mild with few or no symptoms; no 
interventions required
Asymptomatic; clinical or diagnostic 
observations only; intervention not 
indicated
II Moderate, with minimal intervention 
needed; some limitation of activities
Symptomatic; altered GI function
III Severe but not life threatening; 
hospitalization required; limitation 
of patient's ability to care for him or 
herself
Severely altered GI function; bowel rest 
tube feeding; TPN or hospitalization 
indicated
IV Life threatening; urgent intervention 
required
Life-threatening consequences; urgent 
operative intervention indicated
V Death related to adverse event death
Table 2. Explanation of grades of adverse events [76].
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Some side effects are caused by the fact that VEGF impairment impairs wound healing on 
account of its antiangiogenic properties [65]. Gastrointestinal perforation has been known 
to occur in patients on anti-VEGF therapy. In the AVOREN trial, three patients receiving 
bevacizumab in combination with IFN-α experienced grade 4 gastrointestinal perforations, 
while one patient experienced grade 3 gastrointestinal perorations [66]. Sorafenib and suni-
tinib have also been shown to cause gastrointestinal perforations [65]. These perforations are 
caused by tumors, often metastatic, and the healing of these perforations is impaired because 
angiogenesis is itself prevented. Moreover, a significantly increased risk of hemorrhagic 
events of all grades is observed in patients on sorafenib, sunitinib, pazopanib, bevacizumab, 
and aflibercept [65, 75].
6. New directions
Although much progress has been made in angiogenesis inhibition therapy, research in the 
field is still ongoing. The following section reviews (i) how does tumor resistance against anti-
VEGF mediation grow? (ii) what are the challenges in assessing biomarkers for the efficacy 
of antiangiogenic therapies in specific cases? and (iii) how can treatment methodologies and 
new treatments improve overall survival (OS)?
6.1. How does tumor resistance against anti-VEGF medication grow?
Tumor resistance to antiangiogenic therapies can be classified into two broad categories: 
intrinsic and acquired [65, 77]. Acquired antiangiogenic resistance, in contrast to normal meth-
ods of acquired drug resistance in which mutational alteration of the drug target prevent the 
drug from working, consists of tumors initiating alternative methods to cope with hypoxia 
[77]. There are at least four distinct mechanisms through which this acquired resistance oper-
ates: (1) through the activation and upregulation of alternative proangiogenic pathways; (2) 
through the recruitment of bone marrow-derived proangiogenic cells including increased 
pericyte coverage of tumor vasculature; (3) through increased tumor aggressiveness result-
ing in metastasis to provide vasculature through widespread vessel cooption as opposed to 
tumor angiogenesis; and (4) through the adoption of alternative angiogenic mechanisms [77].
6.1.1. Proangiogenic pathways not involving VEGF
Several proangiogenic molecular pathways are upregulated when the VEGF/VEGFR path-
way is inhibited. This often results in a return of tumor vascularization after a period of 
refractoriness [65, 78]. Some examples of alternative proangiogenic pathways include fibro-
blast growth factors (FGFs), platelet-derived growth factors (PDGFs), tumor necrosis factor-α 
(TNF-α), placenta growth factor (PlGF), angiogenin, stromal-derived factor 1α (SDF-1α), 
and interleukins-1α and -1β (IL-1α, IL-1β) [79–81]. Several of these molecules are regulated 
through HIF-1 expression, which in turn is controlled by hypoxia [79]. Therefore, through 
inducing the regression of tumor vasculature, anti-VEGF therapies can induce the expression 
of other proangiogenic pathways that reduce their own efficacy.
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Several therapies are being developed that target both VEGF and alternative angiogenic path-
ways at the same time. For example, blockage of both VEGF and bFGF with brivanib resulted 
in prolonged tumor stasis following previous angiogenic inhibition in mouse neuroendo-
crine tumors [82]. Another study reported that inhibiting SDF-1α after irradiating mice with 
implanted human U251 GBM tumors prevented the revascularization of irradiated tumors 
more effectively than inhibiting VEGF, thereby suggesting that SDF-1α may be involved in 
acquired resistance to anti-VEGF therapies as well [81]. It has also been suggested that syner-
gism between FGF-2 and PDGF-bb could induce angiogenesis, even if they are only present 
at low concentrations within the cytoplasm [79]. Taken together, these results suggest that 
inhibition of alternative angiogenic pathways in addition to inhibiting VEGF could increase 
the efficacy of antiangiogenic therapy.
6.1.2. BMDCs
Bone marrow–derived cells (BMDCs) such as pericytes and macrophages play important 
roles in both normal and pathological angiogenesis [1, 83, 84]. Tumor-associated macrophages 
(TAMs) are attracted to hypoxic regions of tumors through the upregulation of chemoattrac-
tants caused by hypoxia. Following extravasation into the tumor region, monocytes migrate 
into hypoxic areas of the tumor, following a chemoattractant gradient [85]. Monocyte che-
moattractant protein-1 (MCP-1) has been shown to be an important chemoattractant in this 
process [86]. Once in the hypoxic region of the tumor, macrophages will promote tumor pro-
gression and metastasis through their trophic role (breaking down the ECM and encouraging 
tumor cell motility) and through excreting compound such as mutagenic oxygen, nitrogen 
radicals, and several proangiogenic factors such as VEGF and angiopoietin-2 [83, 87].
The process through which pericytes contribute to cancer progression and metastasis is poorly 
understood. Normally, pericytes are associated with newly formed blood vessels, creating a 
single, often discontinuous, layer around the endothelial cell tube that serves to support a 
mature vessel. However, in tumor angiogenesis, pericyte coverage can be greater than, or 
less than normal tissue vasculature depending on the tumor type; for example, glioblastoma 
exhibits lower than normal pericytes coverage, while islet carcinomas exhibit higher than 
normal coverage. This aberrant pericyte coverage can result in tumor growth and metastasis 
[88]. Current pericytes-targeted cancer therapies aim to reach a balance between pro-and anti-
angiogenic factors, encouraging vascular normalization [89].
6.1.3. Increased tumor aggressiveness
In most cancers, the appearance of a proinvasive phenotype following antiangiogenic therapy 
is in question; however, in glioblastoma it is relatively undisputed [78], and there is evidence 
suggesting its occurrence in pancreatic cancer [90]. The proinvasive phenotype allows tumors 
from these cancers to circumvent the need for a blood supply, obviating the necessity of tumor 
angiogenesis. The mechanisms underlying this increased tumor aggressiveness are not fully 
known. HIFs have been widely accepted as playing a role in increased tumor aggressiveness 
and metastasis [90]. Moreover, increased collagen signaling in the presence of VEGF inhibition, 
including activation of discoidin domain receptor 1, protein tyrosine kinase 2, and pseudopo-
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dium-enriched atypical kinase 1, has been shown to increase tumor progression and aggres-
siveness in murine models of pancreatic ductal adenocarcinoma [91]. In glioblastoma, VEGF 
inhibition creates hypoxic conditions in the tumor, which in turn causes increased expression 
of c-Met, an HGF receptor tyrosine kinase, through HIF-1α; this increase in c-Met expres-
sion correlates with increased invasion and poorer survival [80]. When both VEGF and c-Met 
are blocked, the increased tumor invasiveness and aggressiveness associated with anti-VEGF 
medications is suppressed in murine GBM and PNET, suggesting new routes for research in 
antiangiogenic therapies [80, 92].
6.1.4. Alternative angiogenic mechanisms
Another method through which tumors can circumvent angiogenic inhibition is though alter-
native angiogenic mechanisms such as intussusceptive angiogenesis, glomeruloid angiogen-
esis, vasculogenic mimicry, looping angiogenesis, and vessel cooption [78, 83]. These forms 
of angiogenesis occur through other signaling pathways that do not involve VEGF, and are 
upregulated when VEGF signaling is inhibited. One such alternative angiogenic pathway is 
vasculogenic mimicry (VM), which may be encouraged when anti-VEGF medications pro-
vide selective pressure for stem-like cancer cells that participate in the process. This phenom-
enon highlights the need for novel therapeutic methods that target the signaling pathways 
that control VM in addition to VEGF [93]. Similar combination therapies could be used to 
increase the efficacy of antiangiogenic medication in general by restricting the tumor’s ability 
to acquire resistance to antiangiogenic therapies.
6.2. Challenges in biomarkers
Unfortunately, no validated biomarkers are currently available for determining which 
patients will respond best to antiangiogenic therapy [93, 94]. An array of biomarkers has been 
studied in hope to find effective biomarkers, including systemic measurements, gene analy-
sis, circulating biomarkers, tissue markers, and imaging parameters [95]. Various challenges 
stand in the way of establishing effective biomarkers, such as the inability to perform repeated 
biopsies (inhibiting researchers’ ability to assess dynamic biomarkers), the unpredictability of 
response and toxicity, the expensive and complex nature of human trials, the unpredictability 
of toxicity and response to therapies, and the specificity of each biomarker to disease [95].
The degree of hypertension experienced by a patient has been proposed as a potential sys-
temic biomarker of tumor response, although more research is needed to establish the validity 
of this measurement [95, 96, 97]. Because hypertension is dependent on the VEGF-signaling 
pathway, it is possible that patients who do not develop hypertension are not responding to 
VEGF treatment at the current dose. In fact, the degree of hypertension correlates with sur-
vival, with patients who develop more severe hypertension experiencing better cancer remis-
sion than patients who develop no hypertension [97]. Interestingly, VEGF polymorphisms 
may play a role in determining the degree of hypertension, of anti-VEGF medications, which 
certain polymorphisms being more susceptible to inhibition than others. For example, VEGF-
634 SNP (single nucleotide polymorphism) G/G is correlated with higher hypertension in 
suninitib-treated patients with mRCC than either VEGF-634 C/G or VEGF-634 C/C [98].
Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy396
Several circulating biomarkers have been proposed that circulate in the bloodstream of 
patients. For example, high levels of soluble VEGF-R1 (sVEGFR1) correlate with decreased 
efficacy of bevacizumab in GBM, rectal carcinoma, breast cancer, hepatocellular carcinoma, 
and metastatic colorectal carcinoma. This correlation is probably caused by sVEGFR1 acting 
as an endogenous VEGF-trap, so adding a VEGF-specific monoclonal antibody does little 
to further inhibit VEGF signaling pathways [94]. Another potential circulating biomarker is 
SDF1α, as levels of this chemokine correlate with evasion of anti-VEGF therapies, although 
further study is needed to assess this potential biomarker [94]. Pretreatment levels of circu-
lating VEGF-A has been shown to be prognostic in metastatic colorectal, lung, and renal cell 
cancers, but it is not predictive for bevacizumab treatment [99]. Moreover, a phase II study 
presented evidence that plasma concentrations of VEGF-A and IL-8 are prognostic for OS in 
MRCC, with high levels being unfavorable, while low plasma levels or sVEGFR-3 are may be 
predictive for a positive outcome in patients with mRCC receiving sunitinib [100]. Another 
phase II trial found that serum levels of Ang-2 and MMP-2, along with tumor levels of HIF-1α, 
are potential baseline efficacy biomarkers for sunitinib in advanced RCC [101]. Finally, low 
circulating endothelial cell levels (<65 CEC/4 mL blood) have been found to correlate with 
longer median PFS and OS in patients with colorectal cancer receiving bevacizumab [102].
Imaging techniques provide potential of imaging parameters as biomarkers as well. For 
example, MRI- and CT-based tissue vascular measured such as blood flow, blood volume, 
and permeability have been shown to occur after bevacizumab administration, although 
more research is needed to assess the efficacy of these measures as biomarkers [95]. Moreover, 
pretreatment ADC histogram analysis has been shown to be a possible predictive biomarker 
for bevacizumab treatment in recurrent glioblastoma [103]. Imaging studies can also be used 
to augment other biomarker studies, and can be used in cooperation with systems pharma-
cology to create multilevel computational models that predict the efficacy of treatment in 
patients, as well as suggesting dosing schedules that could be more efficacious than current 
practices [104]. Another potential biomarker could be patient genotype. As discussed above, 
some VEGF SNPs may be more receptive to treatment than others. However, some genes 
show little or no correlation with the efficacy of antiangiogenic therapies. For example, the 
mutation status of KRAS, a common oncogene, does not correlate with VEGF therapy efficacy 
[105]. More research must be done to establish which genes can and cannot be considered 
biomarkers.
6.3. Treatment methodologies and new treatments
According to the normalization hypothesis, during the course of antiangiogenic therapy, there 
is a dose-dependent window of time during which aberrant tumor vasculature is normalized. 
In this state, it is easier to deliver cytotoxic drugs from conventional chemotherapy to the tumor 
in a treatment schedule that takes advantage of the window presented by antiangiogenic agents 
given in low doses [106]. However, there are two important considerations to take into account 
when scheduling chemotherapy with antiangiogenic agents: first, the dose of antiangiogenic 
agents affects the normalization window during which chemotherapy can be delivered effec-
tively. Second, the size of the chemotherapeutic agents matters, as vascular normalization 
causes the pores in aberrant tumor vessels to shrink, limiting the ability of large molecules to 
Anti-VEGF Therapy in Cancer: A Double-Edged Sword
http://dx.doi.org/10.5772/66763
397
pass through to the tumor [94]. Vascular normalization has also been shown to improve the out-
come of immunotherapy, making delivery of immune cells to the tumor easier, and can even 
decrease the intravasation of cancer cells, limiting the possibility of metastasis [94].
Most of the time, resistance to chemotherapy occurs through heritable changes in the tumor 
genotype. However, because resistance to VEGF inhibitors does not occur through natural 
selection, as discussed above, it is possible that rechallenging after disease progression fol-
lowing an intervening interval of time during which VEGF therapy is suspended may allow 
for a return of efficacy in antiangiogenic VEGF inhibitors. For example, patients with meta-
static renal cell carcinoma (mRCC) who experience disease progression after initial response 
to sunitinib can eventually respond to the drug upon rechallenge after an intervening period 
on alternative therapies, such as sorafenib (patients with more than 6 months off sunitinib 
experienced greater PFS than patients with less than 6 months off sunitinib, although in each 
case the second PFS was shorter than the original) [99]. Moreover, in a randomized phase 
III trial, patients with unresectable metastatic colorectal cancer progressing up to 3 months 
after discontinuing bevacizumab plus chemotherapy experienced moderate survival benefits 
when bevacizumab plus chemotherapy was given as a second line treatment as compared to 
chemotherapy alone [107].
More research must be done to assess the efficacy of antiangiogenic agents in the adjuvant 
and neoadjuvant settings. In the neoadjuvant setting, VEGF inhibition may cause tumor 
regression, converting an unresectable tumor to a resectable one [82], with 12 of 30 patients 
in one single-arm phase II study who received oxaliplatin plus bevacizumab having initial 
nonsynchronous unresectable CLM become resectable [108]. However, antiangiogenic neoad-
juvant treatment in mouse models of metastatic disease has been shown not to correlate with 
postsurgical survival [109]. In the adjuvant setting, it is possible that antiangiogenic therapies 
may prevent relapse by preventing the reestablishment of tumor vasculature. However, beva-
cizumab has delivered poor results in OS when used in combination with chemotherapy for 
adjuvant colorectal cancer, although PFS is improved [78].
Some work is also being put into developing novel VEGF and VEGFR inhibitors. For example, 
ramucirumab, a monoclonal antibody that inhibits VEGFR-2, was given FDA approval in 
2014 for use as a single agent in the treatment of patients with gastroesophageal carcinoma; it 
has since been given approval for use in combination with paclitaxel, docetaxel, and FOLFIRI 
[110]. Ramucirumab is the first biological treatment to show moderate survival benefits as a 
single agent after gatroesophageal adenocarcinoma progression following first-line chemo-
therapy in a phase 3 trial (ramucirumab vs. placebo, OS = 5.2 months vs. 3.8 months, respec-
tively) [111]. The drug has also shown moderate OS benefits when used in combination with 
docetaxel for second-line treatment of stage IV NNSCLS compared with docetaxel alone after 
progression on platinum-based chemotherapy (10.5 months vs. 9.1 months, ramucirumab 
plus docetaxel vs. docetaxel alone, respectively) [112]. Apatinib is another novel VEGFR-2 
inhibitor, a small molecule not yet given FDA approval (although it is approved for use in 
China in treating metastatic gastric or gastroesophageal adenocarcinoma after second-line 
chemotherapy) [113]. The drug thus far has shown only moderate survival benefits of 1.8 
months, and several trials are ongoing to assess its efficacy in different settings [114].
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Yet another new small molecule VEGF inhibitor, cabozantinib (Cabometyx, Exelixis, Inc.) was 
given FDA approval on 25 April, 2016, for the treatment of renal cell carcinoma in patients 
who have received prior antiangiogenic therapy. Approval was given based on improved 
progression-free survival (7.4 months vs. 3.8 months in the cabozantinib and everolimus arms, 
respectively), improved overall survival (21.4 months vs. 16.5 months) and improved con-
firmed response rate (17 vs. 3%). The drug exhibits the standard side effects associated with 
VEGF inhibition; 40% of patients who received cabozantinib experienced a serious adverse 
event such as abdominal pain, pleural effusion, diarrhea, and nausea [115].
Another potential target for anticancer therapy has also been found in lymphangiogenesis. 
Several studies are examining the potential of inhibiting the VEGFR-3/VEGF-C/VEGF-D 
signaling axis in preventing lymph-node-mediated metastasis and disease progression. 
Inhibition of VEGF-C/-D with soluble VEGFR-3 has been shown to reduce tumor metastasis 
in mouse models, as has blocking VEGF-C/-D proteolysis or blocking VEGF-C from bind-
ing with the Nrp-2 receptor [116]. Moreover, foretinib, a multiple kinase inhibitor currently 
undergoing clinical trials, has shown promise in inhibiting the activity of VEGFR-3 and lym-
phangiogenesis and could potentially be used to inhibit lymph-node-mediated metastasis 
[117]. Corosolic acid has also been shown to induce apoptosis in CT-26 colon carcinoma in a 
mouse model, in addition to inhibiting lymphangiogenesis, but more study is needed before 
this substance becomes useable as a cancer therapy [118].
PlGF inhibition is another potential novel therapeutic approach in the fight against cancer, 
and preclinical studies have shown that inhibiting PlGF using genetic inhibition or anti-PlGF 
antibodies slows tumor growth and metastasis, and can even induce tumor regression in 
preexisting medulloblastoma [119]. However, the efficacy of inhibiting PlGF in tumors has 
come under question, with some preclinical studies showing that inhibiting PlGF does not 
significantly inhibit tumor grows [120, 121]. More research is needed to assess whether PlGF 
inhibition could be an efficacious cancer therapy.
7. Conclusion
Ever since its discovery, VEGF has been at the center of attention in new and developing 
cancer therapies. Since its early successes, however, antiangiogenic therapy has often pre-
sented only modest improvements in overall survival and progression-free survival [122]. 
Researchers have not given up hope that this therapeutic technique contains promise in the 
arsenal against cancer. Therefore, much recent research has been done in pushing the frontier 
of antiangiogenic therapies, trying to improve patient outcome.
Because the biology of VEGF and its receptors is well understood, current research focuses 
on why some tumors become resistant to antiangiogenic therapies and others are intrinsi-
cally resistant, how to circumvent this intrinsic or acquired resistance, and how to best utilize 
these expensive therapies by developing predictive biomarkers for treatment outcome. More 
research is also being done to develop novel VEGF inhibition techniques, and in character-
izing the rare yet serious toxicities associated with these drugs.
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As they stand now, antiangiogenic therapies face a set of limitations that severally impacts 
their efficacy. Tumors can acquire resistance to the drugs (if they do not already have intrinsic 
resistance) and demonstrate an increase in aggressiveness. Moreover, antiangiogenic thera-
pies may cause a decrease in chemotherapy perfusion, lowering the efficacy of chemothera-
pies given in combination with antiangiogenic medicine [123]. These difficulties suggest that, 
at least when given alone, antiangiogenic therapies may face severe limitations in survival 
benefits. Therefore, future research should focus on more than simply inhibiting VEGF on 
a continuous schedule. Rather, it should focus on increasing the efficacy of chemotherapy 
through utilizing antiangiogenic therapy to induce vascular normalization, allowing for more 
efficient delivery of chemotherapeutic agents [123, 124]. Moreover, research should also find 
ways to decrease resistance to these therapies through inhibiting proangiogenic factors that 
are upregulated in response to the inhibition of VEGF and through developing predictive 
biomarkers for the efficacy of these expensive treatments [123, 124].
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